ZFIN Image: Bu et al., 2021, Figure 5

Image

Figure Caption

Figure 5

Distinct cellular effects of mtor and mapk3 inhibition on the VEC model.

(A) Representative images of the nucleus and outline of cardiomyocytes were obtained by immunostaining with anti–myocyte enhancer factor-2 (red) and anti–β-catenin (green) antibodies in WT controls and vmhcl^e13/e13, vmhcl^e13/e13mapk3^e2-MJ, and vmhcl^e13/e13mtor^e6-MJ mutants at 3 dpf. The insets show the boxed areas at higher original magnification. The white arrows indicate nuclei of the cardiomyocytes. Representative cardiomyocytes in the OCR are outlined by dashed white lines in panels with β-catenin staining. A, atrium; V, ventricle; scale bar: 25 μm. (B–G) Quantification of the cardiomyocyte length (B), cardiomyocyte width (C), cardiomyocyte length/width ratio (D), cardiomyocyte nuclei size (E), cardiomyocyte density (F), and cardiomyocyte area (G) measured in these mutants and WT controls. n = 6; data are presented as the mean ± SD; 1-way ANOVA. (H) Schematics of different cellular changes observed upon mapk3 and mtor inhibition in the VEC model. Red indicates changes in cardiomyocyte length (L), width (W), or nuclei size (N).

Figure Data

Expression / Labeling details

Phenotype details

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ JCI Insight